Medistem Panama

Specializing in human umbilical cord, bone marrow and adipose stem cells.

We isolate and produce stem cells and stem cell products for research and safe regenerative medicine treatments by employing the highest quality standards and the latest technological and scientific advances.

Medistem Panama operates an 8,000 sq. ft. laboratory that features 4 ISO 7 clean rooms, 1 ISO 6 clean room, 8 class 100 laminar flow hoods,12 Class A2 biosafety cabinets, and 25 IOS 5 incubators. We are ISO 9001 certified and licensed by the Panamanian Ministry of Health to develop the process of production, expansion and storage of stem cells and stem cell products for therapeutic uses.

In 2008, president and founder, Neil H. Riordan, PA, PhD launched Medistem Panama Inc. at the prestigious City of Knowledge.

Lab technician removing a vial of isolated umbilical cord mesenchymal stem cells from -150°C freezer.

Medistem Inc. has established scientific background and developed technology alongside US universities and important research centers around the world including the University of San Diego, University of Utah, University of Western Ontario, University of Florida and University of Massachusetts.  Our research has led to dozens of scientific publications and seventeen pending patents.

In addition to supplying cellular products to Stem Cell Institute in Panama, we are currently isolating and producing stem cells and stem cell-based products for clinical trials approved by the Comité Nacional de Bioética de la Investigación (CNEI) Institutional Review Board (IRB) in Panama.

The first published clinical trial is Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.

Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism is complete and we anticipate the results will be published in a peer-reviewed scientific journal later this year.

The last clinical trial, Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis, is currently active but not recruiting patients.

In addition to supplying stem cells and technology to Stem Cell Institute and ongoing clinical trials in Panama, human umbilical cord tissue-derived mesenchymal stem cells (MSCs) that were isolated and grown at Medistem to create master cell banks are currently being used in the United States under US FDA regulation.  These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient).